PR Newswire All News ReleasesCodex · 实盘不做把握 6/10不做原因:无增量信息
北京时间·🕒 发布 07:01:00·⟳ 抓取 07:09:49 +8m49s·⚡ 决策 08-25 07:13:12 +3m23s·63.7 天前
Rosen律所发布Aardvark证券集体诉讼征集公告，未新增ARD-101安全性或监管事实
本次Rosen公告没有新增临床、监管、法院或赔偿量级事实；对AARD.US偏负面但边际信息弱，无法形成正期望新开空仓。
📄 原文PR Newswire All News Releases↗ 原文
AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action law…
不做 Aardvark Therapeutics, Inc.（AARD.US）
不做：本次为已filed证券诉讼的律所征集公告，底层ARD-101 clinical hold和诉讼事项均已公开，缺少新的强空催化和可量化法律损害。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Aardvark的实质风险来自ARD-101安全性与FDA clinical hold，证券诉讼只是围绕该旧事实追索披露责任。本次Rosen公告距离抓取仅约9分钟但不是首个诉讼披露节点，2026-08-17已有同类class action filed公告；直接交易载体仅AARD.US，未发现可交易ADR或单股杠杆产品，且没有二阶传播标的。方向偏负面但新增事实不足，不做新多也不开新空。
消息传播链
- 公司披露FDA对ARD-101 IND实施full clinical hold，这是诉讼指向的底层实质安全性/监管风险。市场反应:AARD.US在该底层事件后已发生主要重定价。
- 已有律所公告称针对Aardvark的证券集体诉讼已经filed，诉讼期和核心指控与本次Rosen公告一致。
- Rosen发布首席原告征集公告，重复说明诉讼已filed和2026-10-13截止日。市场反应:发布时美股已处盘后不可连续成交时段。
关键理由
- Rosen公告延续ARD-101安全性披露争议，但未披露新的临床数据、FDA动作或法院进展。
- 同一class action filed信息已在2026-08-17由其他律所公开，本次新增主要是首席原告征集截止日。
- Aardvark仍是临床阶段公司，诉讼公告未给出赔偿金额或现金流损害，无法量化新的市值冲击。
主要风险
- 若后续法院认证class、出现和解金额、SEC/DOJ调查或FDA维持长期hold，AARD.US可能出现新的可交易利空。
- 小市值临床阶段biotech波动和跳空风险高，单独依据重复律所PR做空容易被反弹挤压。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-08-17 · 影响 invalidates
同一诉讼已在8月17日由其他律所发布，削弱8月24日Rosen PR作为新开空催化的边际性。
检索:AARD class action filed August 17 2026 already filed Rosen August 24 duplicate 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-11 · 影响 weakens
公司仍在评估unblinded HERO/OLE数据并与FDA讨论，未见本次公告新增破产、停运或立即现金流损害事实。
检索:Aardvark Therapeutics ARD-101 clinical hold August 2026 update cash runway 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足与新增事实弱共同压低置信度和仓位，最终不把AARD.US升级为ENTER SHORT。
方向:同类律所证券诉讼征集对被告公司方向偏负面，但若底层临床或监管利空已先行披露，重复征集公告通常只是弱边际负面。
涨幅量级:缺少高相似、同市场、同相位且锚点干净的重复律所PR先例，不能据此设定做空幅度。
形态:本次可迁移模式是底层FDA clinical hold驱动主要反应，后续律所PR更容易成为已知风险扩散而非新催化。
原文全文
展开原文 · 4,130 字
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026.
So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
So what: If you purchased Aardvark securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
What to do next: To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
Details of the case: According to the lawsuit, in the Registration Statement and throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Aardvark's business, operations, and prospects. Specifically, defendants failed to disclose to investors that: (1) ARD-101 was less safe than defendants had led investors to believe; (2) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Aardvark class action, go to https://rosenlegal.com/cases/aardvark-therapeutics-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com
SOURCE THE ROSEN LAW FIRM, P. A.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。